Review ArticleReviewsR
The Kynurenine Pathway: A Primary Resistance Mechanism in Patients with Glioblastoma
PETER P. SORDILLO, LAURA A. SORDILLO and LAWRENCE HELSON
Anticancer Research May 2017, 37 (5) 2159-2171;
PETER P. SORDILLO
1SignPath Pharma, Inc., Quakertown, PA, U.S.A.
2Department of Hematology and Oncology, Lenox Hill Hospital, New York, NY, U.S.A.
LAURA A. SORDILLO
1SignPath Pharma, Inc., Quakertown, PA, U.S.A.
LAWRENCE HELSON
1SignPath Pharma, Inc., Quakertown, PA, U.S.A.
In this issue
The Kynurenine Pathway: A Primary Resistance Mechanism in Patients with Glioblastoma
PETER P. SORDILLO, LAURA A. SORDILLO, LAWRENCE HELSON
Anticancer Research May 2017, 37 (5) 2159-2171;
Jump to section
Related Articles
- No related articles found.
Cited By...
- Suppression of Kynurenine 3-Monooxygenase as a Treatment for Triple-negative Breast Carcinoma
- Humanized PD-1 Knock-in Mice Reveal Nivolumabs Inhibitory Effects on Glioblastoma Tumor Progression In Vivo
- AHR agonist ITE boosted PD1 antibodys effects by inhibiting myeloid-derived cells suppressive cells in an orthotopic mouse glioma model
- The Mystery of Chemotherapy Brain: Kynurenines, Tubulin and Biophoton Release
- MYC promotes tryptophan uptake and metabolism by the kynurenine pathway in colon cancer
- Alterations in Cell Motility, Proliferation, and Metabolism in Novel Models of Acquired Temozolomide Resistant Glioblastoma
- Intense Uptake of Liposomal Curcumin by Multiple Myeloma Cell Lines: Comparison to Normal Lymphocytes, Red Blood Cells and Chronic Lymphocytic Leukemia Cells